Psychemedics (PMD) 20.27 $PMD Psychemedics Up 45.2%

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Psychemedics (PMD) 20.27 $PMD

Psychemedics Up 45.2% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Tue Aug 30, 12:26AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 2 months, Psychemedics has returned 45.23% as of today's recent price of $21.00.
PMD: 20.27 (-0.48)

48.6% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Mon Aug 22, 12:55PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 2 month, Psychemedics has returned 48.62% as of today's recent price of $21.49.
PMD: 20.27 (-0.48)

33.2% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Fri Aug 12, 1:17PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 1 month, Psychemedics has returned 33.17% as of today's recent price of $19.26.
PMD: 20.27 (-0.48)

Psychemedics Has Returned 43.3% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Fri Aug 05, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 4 weeks, Psychemedics has returned 43.29% as of today's recent price of $20.72.
PMD: 20.27 (-0.48)

Psychemedics Up 24.6% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Jul 28, 1:38PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 8th, 2016 at $14.46. In approximately 3 weeks, Psychemedics has returned 24.55% as of today's recent price of $18.01.
PMD: 20.27 (-0.48)

Shares of PMD Up 27.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 17, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 4 months, Psychemedics has returned 27.45% as of today's recent price of $13.00.
PMD: 20.27 (-0.48)

Psychemedics Up 37.0% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Mon May 09, 1:18PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 36.96% as of today's recent price of $13.97.
PMD: 20.27 (-0.48)

Shares of PMD Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 29, 1:02PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 39.80% as of today's recent price of $14.26.
PMD: 20.27 (-0.48)

Psychemedics posts 1Q loss
Automated Insights - Tue Apr 26, 5:21PM CDT
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Tuesday reported a first-quarter loss of $23,000, after reporting a profit in the same period a year earlier.
PMD: 20.27 (-0.48)

Psychemedics Corporation Announces Quarterly Results
PR Newswire - Tue Apr 26, 4:45PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 6, 2016 to be paid on May 18, 2016. This will be the Company's 79th consecutive quarterly dividend.
PMD: 20.27 (-0.48)

Shares of PMD Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 21, 12:55AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 43.09% as of today's recent price of $14.60.
PMD: 20.27 (-0.48)

Psychemedics Has Returned 37.7% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Apr 13, 1:30PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 2 months, Psychemedics has returned 37.75% as of today's recent price of $14.05.
PMD: 20.27 (-0.48)

Psychemedics Has Returned 26.1% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Tue Mar 29, 1:47PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 2 months, Psychemedics has returned 26.08% as of today's recent price of $12.86.
PMD: 20.27 (-0.48)

Psychemedics posts 4Q profit
Automated Insights - Wed Feb 10, 5:25PM CST
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Wednesday reported fourth-quarter net income of $185,000.
PMD: 20.27 (-0.48)

Psychemedics Corporation Announces Quarterly And Annual Results
PR Newswire - Wed Feb 10, 4:20PM CST
Psychemedics Corporation (NASDAQ MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2015. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 22, 2016 to be paid on March 4, 2016. This will be the Company's 78th consecutive quarterly dividend.
PMD: 20.27 (-0.48)

BUYINS.NET: PMD SqueezeTrigger Price is $10.29. There is $378,290 That Short Sellers Still Need To Cover.
M2 - Tue Feb 09, 10:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring PetroMagdalena Energy Corp (NASDAQ MD) in real time and just received an alert that PMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 36200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.29. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
PMD: 20.27 (-0.48)

Shares of PMD Down 21.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 28, 10:47AM CST
SmarTrend identified a Downtrend for Psychemedics (NASDAQ MD) on December 29th, 2015 at $10.20. In approximately 1 month, Psychemedics has returned 21.53% as of today's recent price of $8.00.
PMD: 20.27 (-0.48)

North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 20.27 (-0.48), BRLI: 34.69 (+0.08), ALR: 39.13 (-0.18), ARDX: 9.97 (-0.53), GHDX: 26.47 (+0.31), ENZ: 5.56 (-0.12)

Latin America, Africa & Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2016 to 2019
M2 - Mon Jan 25, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/nlg4t5/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Latin America, Africa & Middle East" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Report Highlights - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions - Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand - Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges - Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth - Again, assistance in using the information is normally provided without additional charges Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 2.5 National and Regional Diversity 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Latin America, Africa & The Middle East 6. The Future of the Clinical Laboratory Key Companies - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Mid America Clinical Laboratories, LLC - Alere Inc - Caris Life Sciences, Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Pathology Inc. - Gribbles Pathology - BP Lab - Adicon Clinical Laboratories, Inc. - Diagn?sticos da Am?rica (DASA) - Medicus Phillipines Inc. - Kingmed Diagnostics - Ascend Clinical, LLC - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/nlg4t5/clinical
PMD: 20.27 (-0.48), MYGN: 20.36 (-0.18), ALR: 39.13 (-0.18), ARDX: 9.97 (-0.53), GHDX: 26.47 (+0.31), DGX: 82.82 (-0.72)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading